Fresenius Medical Care stock carries Q2 growth into its Q3 report

Published on 10/05/2026 at 22:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock was last at EUR 40.25 on Xetra on October 5, 2026, down 0.33 percent. Q2 revenue reached USD 5.55 billion against USD 5.48 billion expected.

Modernes Klinik-Atrium mit Glasdach, hellem Eingangsbereich und Pflanzen — Ein helles, weitläufiges Klinik-Atrium mit Glasdach und modernem Eingangsbereich – architektonisch vergleichbar mit den Dialysezentren und Gesundheitseinrichtungen von Fresenius Medical Care AG (ISIN DE0005785802) weltweit, Illustration mit AI erstellt.

Fresenius Medical Care stock (ISIN DE0005785802) was last at EUR 40.25 on Xetra on October 5, 2026, down 0.33 percent on the session. The company enters the next reporting cycle with its 2026 outlook confirmed and a third-quarter report scheduled for November 3, 2026, according to Fresenius Medical Care.

Q2 revenue beat expectations

Fresenius Medical Care reported USD 5.55 billion in Q2/2026 revenue, compared with USD 5.48 billion expected, while adjusted earnings reached USD 0.66 per share against a USD 0.62 consensus estimate, MarketBeat reported on September 25, 2026. The revenue figure was USD 70 million above consensus, while adjusted earnings exceeded expectations by USD 0.04 per share.

The company said its underlying operating result improved 34 percent in the first half of 2026 after adjusting for positive TDAPA effects. Care Delivery provided the main operating contribution, while the 5008X CAREsystem had reached 227 US clinics and more than 600,000 treatments, according to Fresenius Medical Care.

Analysts see limited upside

Goldman Sachs cut its FMC price target from EUR 39 to EUR 38 and kept a Neutral rating on September 30, 2026. Analyst Richard Felton cited an expected modest increase in treatment volumes, while his adjusted operating profit forecast of EUR 524 million stood above consensus, according to FinanzNachrichten.

Berenberg took a more forceful position on September 29, 2026, lowering its target from EUR 60 to EUR 42 and cutting its rating from Buy to Hold. The bank pointed to fading self-driven growth impulses and the potential overhang from Fresenius reducing its stake, according to FinanzNachrichten.

Consensus target stays above EUR 40

The published consensus covers 17 analysts and carries a Neutral label, with an average 12-month target of EUR 41.685, a high of EUR 67 and a low of EUR 30. Against the EUR 40.25 Xetra price on October 5, 2026, the average target lies 3.6 percent above the share price, according to Investing.com.

FMC stock stays below its yearly high

FMC stock was last at EUR 40.25 on Xetra at 5:35 p.m. CEST on October 5, 2026, while its 52-week range stood at EUR 34.57 to EUR 47.86 as of October 4, 2026. Market capitalization was EUR 10.5 billion on October 4, 2026.